Beverley Carr appointed Chief Business Officer for Amphista Therapeutics

pharmafile | November 2, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing amphista, appointments 

Amphista Therapeutics have appointed Beverley Carr Chief Business Officer. Amphista is a leader in next generation targeted protein degradation (TPD) approaches.

Beverley Carr commented: “I’m delighted to join Amphista’s world-class team. Amphista is founded on transformational science and I’m looking forward to driving the Company’s business development strategy as we execute our mission of building the leading TPD company.”

Amphista’s CEO Dr Nicola Thompson said: “On behalf of the Amphista team, I am thrilled to welcome Beverley as our CBO. Beverley brings a wealth of business development expertise from an impressive career as a business leader, spanning both Pharma and Biotech.”

Related Content

Sanofi axes four major players from its executive committee

Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …


Dr Richard Torbett is named as the new Chief Executive of the ABPI

The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its …


Insys Therapeutics names current CFO Andrew Long as company’s new CEO

Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s …

Latest content